TY - JOUR
T1 - Striking a balance
T2 - the Goldilocks effect of CD8α expression on NK cells
AU - Dodhiawala, Paarth B.
AU - Cichocki, Frank
N1 - Publisher Copyright:
Copyright: © 2024, Dodhiawala et al.
PY - 2024
Y1 - 2024
N2 - NK cells are cytotoxic innate immune cells involved in antitumor immunity, and they provide a treatment option for patients with acute myeloid leukemia (AML). In this issue of the JCI, Cubitt et al. investigated the role of CD8α, a coreceptor present on approximately 40% of human NK cells. IL-15 stimulation of CD8α- NK cells induced CD8α expression via the RUNX3 transcription factor, driving formation of a unique induced CD8α (iCD8α+) population. iCD8α+ NK cells displayed higher proliferation, metabolic activity, and antitumor cytotoxic function compared with preexisting CD8α+ and CD8α- subsets. Therefore, CD8α expression can be used to define a potential dynamic spectrum of NK cell expansion and function. Because these cells exhibit enhanced tumor control, they may be used to improve in NK cell therapies for patients with AML.
AB - NK cells are cytotoxic innate immune cells involved in antitumor immunity, and they provide a treatment option for patients with acute myeloid leukemia (AML). In this issue of the JCI, Cubitt et al. investigated the role of CD8α, a coreceptor present on approximately 40% of human NK cells. IL-15 stimulation of CD8α- NK cells induced CD8α expression via the RUNX3 transcription factor, driving formation of a unique induced CD8α (iCD8α+) population. iCD8α+ NK cells displayed higher proliferation, metabolic activity, and antitumor cytotoxic function compared with preexisting CD8α+ and CD8α- subsets. Therefore, CD8α expression can be used to define a potential dynamic spectrum of NK cell expansion and function. Because these cells exhibit enhanced tumor control, they may be used to improve in NK cell therapies for patients with AML.
UR - http://www.scopus.com/inward/record.url?scp=85200298258&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85200298258&partnerID=8YFLogxK
U2 - 10.1172/JCI182905
DO - 10.1172/JCI182905
M3 - Review article
C2 - 39087476
AN - SCOPUS:85200298258
SN - 0021-9738
VL - 134
JO - Journal of Clinical Investigation
JF - Journal of Clinical Investigation
IS - 15
M1 - e182905
ER -